Bubendorf Lukas, Lantuejoul Sylvie, de Langen Adrianus J, Thunnissen Erik
Institut für Pathologie, Universität Basel, Basel, Switzerland.
Dept of Biopathology, Centre Léon Bérard UNICANCER, Lyon, France.
Eur Respir Rev. 2017 Jun 28;26(144). doi: 10.1183/16000617.0007-2017. Print 2017 Jun 30.
The pathological and molecular classification of lung cancer has become substantially more complex over the past decade. For diagnostic purposes on small samples, additional stains are frequently required to distinguish between squamous cell carcinoma and adenocarcinoma. Subsequently, for advanced nonsquamous cell nonsmall cell lung carcinoma (NSCLC) patients, predictive analyses on epidermal growth factor receptor, anaplastic lymphoma kinase and ROS1 are required. In NSCLCs negative for these biomarkers, programmed death ligand-1 immunohistochemistry is performed. Small samples (biopsy and cytology) require "tissue" management, which is best achieved by the interaction of all physicians involved.
在过去十年中，肺癌的病理和分子分类变得复杂得多。出于对小样本的诊断目的，经常需要额外的染色来区分鳞状细胞癌和腺癌。随后，对于晚期非鳞状非小细胞肺癌（NSCLC）患者，需要对表皮生长因子受体、间变性淋巴瘤激酶和ROS1进行预测分析。对于这些生物标志物阴性的NSCLC患者，需进行程序性死亡配体-1免疫组织化学检测。小样本（活检和细胞学样本）需要“组织”管理，这最好通过所有相关医生的相互协作来实现。
Zotero 插件
